Payment overview · 2025
General Payments
$224.25
12 reported records · 4 companies
Healthcare provider profile · identity verified
Robert L Hartzell, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BROOKSVILLE, FL · NPI 1154414449
Verified facts
What the public records show
CMS Open Payments records show Robert L Hartzell, M.D. received $224.25 in general payments during 2025 across 12 reported records.
AstraZeneca Pharmaceuticals LP accounted for 65.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Paxlovid.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $146.88 | 65.5% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $35.08 | 15.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $27.15 | 12.1% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.14 | 6.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $224.25 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $65.11 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $37.72 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $27.15 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $17.97 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.11 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.11 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 82 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 26 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
90 | 22 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
57 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
82 | 33 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
26 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1031 | 298 |
| Amlodipine Besylate | Amlodipine Besylate | 683 | 187 |
| Levothyroxine Sodium | Levothyroxine Sodium | 647 | 173 |
| Lisinopril | Lisinopril | 592 | 165 |
| Losartan Potassium | Losartan Potassium | 533 | 153 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 494 | 155 |
| Simvastatin | Simvastatin | 473 | 128 |
| Metformin Hcl | Metformin Hcl | 462 | 128 |
| Hydrochlorothiazide | Hydrochlorothiazide | 373 | 99 |
| Omeprazole | Omeprazole | 364 | 106 |
| Metoprolol Tartrate | Metoprolol Tartrate | 344 | 95 |
| Pantoprazole Sodium | Pantoprazole Sodium | 339 | 115 |
| Furosemide | Furosemide | 323 | 95 |
| Tamsulosin Hcl | Tamsulosin Hcl | 320 | 106 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 317 | 100 |
| Clopidogrel | Clopidogrel Bisulfate | 316 | 93 |
| Gabapentin | Gabapentin | 308 | 98 |
| Pravastatin Sodium | Pravastatin Sodium | 234 | 67 |
| Alendronate Sodium | Alendronate Sodium | 230 | 75 |
| Famotidine | Famotidine | 212 | 58 |
| Alprazolam | Alprazolam | 210 | 52 |
| Atenolol | Atenolol | 205 | 52 |
| Escitalopram Oxalate | Escitalopram Oxalate | 192 | 58 |
| Glipizide | Glipizide | 191 | 55 |
| Potassium Chloride | Potassium Chloride | 189 | 59 |
| Trazodone Hcl | Trazodone Hcl | 165 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 160 | 63 |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 158 | 45 |
| Ezetimibe | Ezetimibe | 150 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 150 | 43 |
| Tramadol Hcl | Tramadol Hcl | 141 | 37 |
| Allopurinol | Allopurinol | 135 | 39 |
| Methylprednisolone | Methylprednisolone | 132 | 122 |
| Carvedilol | Carvedilol | 129 | 42 |
| Warfarin Sodium | Warfarin Sodium | 128 | 26 |
| Temazepam | Temazepam | 117 | 19 |
| Meloxicam | Meloxicam | 115 | 42 |
| Finasteride | Finasteride | 110 | 36 |
| Glimepiride | Glimepiride | 110 | 33 |
| Sertraline Hcl | Sertraline Hcl | 106 | 32 |
| Lovastatin | Lovastatin | 101 | 26 |
| Lorazepam | Lorazepam | 98 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 95 | 26 |
| Symbicort | Budesonide/Formoterol Fumarate | 90 | 22 |
| Azithromycin | Azithromycin | 88 | 77 |
| Montelukast Sodium | Montelukast Sodium | 86 | 21 |
| Eliquis | Apixaban | 82 | 33 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 82 | 23 |
| Buspirone Hcl | Buspirone Hcl | 81 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 76 | 25 |
| Mupirocin | Mupirocin | 62 | 38 |
| Prednisone | Prednisone | 60 | 33 |
| Clonazepam | Clonazepam | 58 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 58 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 57 | 12 |
| Donepezil Hcl | Donepezil Hcl | 55 | 14 |
| Amoxicillin | Amoxicillin | 53 | 44 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 53 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 53 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | 18 |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 52 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 52 | 15 |
| Enalapril Maleate | Enalapril Maleate | 51 | 14 |
| Meclizine Hcl | Meclizine Hcl | 51 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 51 | 14 |
| Celecoxib | Celecoxib | 49 | 18 |
| Cefdinir | Cefdinir | 46 | 40 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 46 | 37 |
| Terazosin Hcl | Terazosin Hcl | 44 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 43 | 12 |
| Ketoconazole | Ketoconazole | 43 | 26 |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 41 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 40 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 40 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 37 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 39 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 38 | suppressed |
| Diazepam | Diazepam | 38 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 38 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | 12 |
| Synthroid | Levothyroxine Sodium | 38 | 11 |
| Folic Acid | Folic Acid | 37 | 13 |
| Nifedipine Er | Nifedipine | 36 | 12 |
| Spironolactone | Spironolactone | 36 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 29 |
| Farxiga | Dapagliflozin Propanediol | 35 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 35 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 34 | 13 |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Benzonatate | Benzonatate | 33 | 25 |
| Jardiance | Empagliflozin | 33 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 33 | 12 |
| Clonidine Hcl | Clonidine Hcl | 32 | suppressed |
| Ozempic | Semaglutide | 32 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Jantoven | Warfarin Sodium | 31 | suppressed |
| Naproxen | Naproxen | 30 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | 19 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 23 |
| Baclofen | Baclofen | 26 | 17 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 26 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 26 |
| Tadalafil | Tadalafil | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 13 |
| Ibuprofen | Ibuprofen | 25 | 13 |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | 13 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 22 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 21 | suppressed |
| Glyburide | Glyburide | 20 | suppressed |
| Sotalol | Sotalol Hcl | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 19 | suppressed |
| Gemfibrozil | Gemfibrozil | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 15 |
| Irbesartan | Irbesartan | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | 15 |
| Primidone | Primidone | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Ssd | Silver Sulfadiazine | 14 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Lumigan | Bimatoprost | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | 11 |
| Estradiol | Estradiol | 11 | suppressed |
| Etodolac | Etodolac | 11 | suppressed |
| Klor-Con 10 | Potassium Chloride | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $224.25 · 12 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, ELIQUIS, JARDIANCE, NURTEC ODT, PAXLOVID, SHINGRIX | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error